The aim of this study was to evaluate in vitro the permeation of the antioxidant agent Idebenone (IDE) loaded into solid lipid nanoparticles (SLN) across MDCKII-MDR1 cell monolayer, selected as an in vitro model of the Blood Brain Barrier (BBB). SLN were prepared using cetyl palmitate as solid lipid and different non-ionic surfactants, oleth-20, ceteth-20 and isoceth-20, by the phase inversion temperature (PIT) technique. The resulting SLN showed physiological pH and osmolarity values, a mean particle diameter in the range of 33-63 nm, a single peak in size distribution, and a potential ranging from +3.14 to −2.89 mV. When incubating these SLN in Simulated Body Fluid (SBF), the particle size was maintained for all samples throughout the study. IDE permeability across MDCKII-MDR1 cell monolayers from the SLN under investigation was 0.40-0.53 fold lower than free IDE and no significant difference was observed comparing IDE permeation from all the SLN tested. It is noteworthy that IDE loading into SLN avoided the use of an organic solvent to solubilize IDE, a poor water soluble compound, allowing the parenteral administration of this drug in aqueous vehicles. Furthermore, the results of in vitro transport studies, performed using fluoresceindextran 4000 (FD4) and diazepam (DZ) as markers of the paracellular pathway and the transcellular pathway, respectively, pointed out that IDE could permeate via a transcellular pathway. Therefore, these novel nanocarriers could be regarded as a promising strategy to design delivery systems for IDE administration to the brain, deserving further investigations under in vivo conditions.
INTRODUCTION
In recent years, solid lipid nanoparticles (SLN) have received increasing attention in modified drug delivery systems. 1 2 The main benefits connected to the use of SLN include the capability to achieve a controlled drug release, 3 4 to increase drug stability and they have been successfully exploited for several routes of administration (topical, oral, ocular and parenteral). 5 In this context, the feasibility of using SLN as colloidal carriers for drug delivery to the brain has been widely reported. [6] [7] [8] Owing to their lipophilic features and their small particle size, SLN could reach the Central Nervous System (CNS), overcoming the blood-brain barrier (BBB) by endocytosis or transcytosis mechanism occurring in the endothelial cells lining blood capillaries in the brain, or they could permeate the tight junctions between endothelial cells. 9 10 Moreover, retention of SLN in brain blood capillaries with absorption into capillary walls could occur * Author to whom correspondence should be addressed. and create a higher drug concentration gradient, leading to enhanced drug transport across the endothelial cells. 9 10 Different methods have been developed to prepare SLN and the most commonly used are high-pressure (hot or cold) homogenization, solvent emulsification/evaporation, dilution of oil-in-water microemulsions. [11] [12] Hot homogenization allows to obtain particles with very small sizes but due to the fact that it is performed at temperatures above the melting point of the lipid, it may increase the degradation rate of the drug and the carrier and the lipid crystallization may be retarded due to the formation of a supercooled melt. 13 High-pressure cold homogenization generally provides larger particle sizes and broader size distribution compared to hot homogenization. 12 The solvent emulsification/evaporation technique allows to obtain SLN with very small particle sizes without involving any thermal stress. 14 However, an important drawback of this technique is the use of organic solvents during the preparation procedures. The technique based on dilution in cold water of oil-in-water microemulsions (MEs) allows Montenegro et al. In Vitro Evaluation on a Model of Blood Brain Barrier of Idebenone-Loaded Solid Lipid Nanoparticles to overcome some of the disadvantages connected to other techniques. 15 However, it may require the use of high surfactant concentrations to prepare the initial ME, which could represent an important limit to its pharmaceutical application.
Recently, we have developed a novel technique to prepare SLN using the phase inversion temperature (PIT) method, obtaining SLN with interesting physico-chemical and technological properties such as good stability, small particle size, narrow size distribution and good loading capacity. 16 This method allowed us to prepare SLN using low amounts of surfactants and avoiding the use of any organic solvent. Such SLN were loaded with the neuroprotective agent idebenone (IDE, Fig. 1 ), whose antioxidant activity has been proposed to be beneficial in the treatment of neurodegenerative diseases. 17 For instance, owing to its ability to inhibit lipid peroxidation, 18 IDE was found to induce protection from neuronal damage such as stroke, intoxication, memory loss and it also improves recovery after brain trauma. 19 Preliminary in vitro biological studies, performed on these IDE-loaded SLN, demonstrated that they did not cause any cytotoxic effect and showed better antioxidant properties compared to free IDE when assessed in primary cultures of rat astrocytes. 16 Since an essential requisite for these SLN to be effective in the treatment of brain disorders is their ability to deliver the loaded drug across the BBB, in this study we investigated the effects of different compositions of SLN prepared by the PIT method on IDE permeation from IDEloaded SLN across MDCKII-MDR1 monolayers, taken as an in vitro model of BBB. 20 The development of MDCKII-MDR1 cell line as a model to screen the permeability across the BBB has been very useful not only to predict drug permeation features of different drugs but also to provide uptake data in full agreement with the ones derived from in vivo mouse brain uptake assay. 21 22 Therefore, IDE-loaded SLN were used to investigate IDE transport across MDCKII-MDR1 and elucidate the mechanism of the bypass of the BBB on the basis that these SLN were designed to be delivered to the brain only by passive diffusion due to their small particle size 16 and the lack of any targeting moiety. Two non-radioactive compounds, namely fluorescein-dextran 4000 (FD4) and diazepam (DZ), were adopted in in vitro transport experiments, as markers of the paracellular and transcellular pathway, respectively. 23 The emulsifying systems and the solid lipid used to prepare IDE-loaded SLN were selected from previous studies of ours. 16 24 Non-ionic surfactants, namely isoceteth-20, oleth-20 and ceteth-20, were used because of their low toxicity compared to ionic ones. Cetyl palmitate was chosen as solid lipid because it has been reported to be safe to prepare SLN intended for systemic administration. [25] [26] [27] The resulting SLN were characterized in terms of both physicochemical properties (morphology, size, polidispersity index, zeta potential, pH, osmolarity, stability during storage) and stability in simulated body fluid (SBF). ® , oleth-20) was supplied by Sigma Aldrich (USA) and fluorescein-dextran 4000 (FD4) was purchased from Sigma-Aldrich (Italy). Methylchloroisothiazolinone and methylisothiazolinone (Kathon CG ® , and imidazolidinyl urea were kindly supplied by Sinerga (Italy). Methanol and water used in the HPLC procedures were of LC grade and were bought from Merck (Germany). All other reagents were of analytical grade and they were used as supplied. Table I and they were prepared using the phase inversion temperature (PIT) method as previously reported. 16 The aqueous phase was a phosphate buffer (pH 7.4) consisting of: (a) NaCl 4.60 g/l, phosphate monobasic 0.64 g/l and phosphate dibasic 5.0 g/l for the preparation of SLN A (containing isoceteth-20/glyceryl oleate); (b) NaCl 3.0 g/l, phosphate monobasic 0.60 g/l and phosphate dibasic 6.40 g/l for the preparation of SLN B and C (containing ceteth-20/glyceryl oleate and oleth-20/glyceryl oleate, respectively).
MATERIALS AND METHODS

Preparation of SLN
SLN composition is reported in
Both buffers contained 0.35% w/w imidazolidinyl urea and 0.05% w/w methylchloroiso-thiazolinone and methylisothiazolinone as preservatives.
The aqueous phase and the oil phase (cetyl palmitate and the selected emulsifiers) were separately heated at ∼90 C; then the aqueous phase was added drop by drop, at constant temperature and under agitation, to the oil phase. The mixture was then cooled to room temperature under slow and continuous stirring.
At the phase inversion temperature (PIT) the turbid mixture turned into clear. 
Size and Zeta Potential Measurements of SLN
For freshly prepared particles, the mean particle size and the size distribution were determined in double distilled water by dynamic light scattering (DLS) using Zetasizer NanoZS (ZEN 3600, Malvern, Germany). Samples were measured after dilution (1:1, sample/water) at 25 C and adjusted to the temperature 2 min prior to the measurement. The autocorrelation functions were analyzed using the DTS v 5.1 software provided by Malvern. Measurements were done in triplicate with 20 runs each and the calculated mean values were used. The determination of the -potential was performed using the technique of laser Doppler velocimetry using Zetasizer NanoZS after dilution with KCl 1 mM (pH 7.0), according to a procedure already reported. 28 
Transmission Electron Microscopy (TEM)
For negative-staining electron microscopy, 5 l of SLN dispersions were placed on a 200-mesh Formvar copper grid (TAAB Laboratories Equipment, UK), and allowed to be adsorbed. Then, the surplus was removed by filter paper. A drop of 2% (w/v) aqueous solution of uranyl acetate was added over 2 min. After the removal of the surplus, the sample was dried at room condition before imaging the SLN with a transmission electron microscope (model JEM 2010, Jeol, Peabody, MA, USA) operating at an acceleration voltage of 200 KV.
Differential Scanning Calorimetry (DSC) Analyses
DSC studies were performed using a Mettler TA STAR e System equipped with a DSC 822 e cell and a Mettler STAR e V. 8.10 software. The reference pan was filled with 100 l of the same phosphate buffer used to prepare the SLN under investigation. The calorimetric system was calibrated, in transition temperature and enthalpy changes, by using indium and palmitic acid (purity ≥ 99 95% and ≥99.5%, respectively; Fluka, Switzerland) and following the procedure of the Mettler STAR e software. 100 l of each sample was transferred into a 160 l calorimetric pan, hermetically sealed and submitted to DSC analysis as follows: (i) a heating scan from 5 to 65 C, at the rate of 2 C/min; (ii) a cooling scan from 65 to 5 C, at the rate of 4 C/min, for at least three times. Each experiment was carried out in triplicate.
Stability Tests
Samples of SLN were stored in airtight jars, and then kept in the dark at room temperature and at 37 C for two months, separately.
Particle size, polidispersity index, pH and osmolarity of the samples were measured at fixed time intervals (24 hours, one week, two weeks, three weeks, one month, and two months) after their preparation. A pH-meter (CRISON, mod. Basic 20, Italy) was used to measure pH values. Osmolarity was determined using an osmometer Osmomat, mod. 030-D (Gonotec, Germany) that was calibrated with a sample of normal saline (300 mOsm/kg).
SLN Stability in Simulated Body Fluid (SBF)
Unloaded and IDE loaded SLN were freshly prepared and the amount of particles was adjusted to obtain two different IDE concentrations, 300 M (SLN A L1 -C L1 and 150 M (SLN A L2 -C L2 , in a solution of Simulated Body Fluid (SBF). 29 30 The SBF had the following composition: NaCl 130.0 mM, NaHCO 3 4.2 mM, KCl 3.0 mM, K 2 HPO 4 1.0 mM, MgCl 2 6H 2 O 1.5 mM, CaCl 2 2.5 mM, Na 2 SO 4 0.5 mM. pH was adjusted to 7.2 and the osmolarity was 300 mOsm/Kg. The resulting suspensions of SLN in SBF were then stored in a thermostatic bath at 37 C, operating at 100 rpm for 24 hours. At different time intervals (0, 1 h, 2 h, 4 h, 6 h and 24 h), particle size of the samples was determined, after equilibration at room temperature. Before dilution for particle sizing (1:1, sample/water), samples were left to equilibrate to room temperature. In Vitro Evaluation on a Model of Blood Brain Barrier of Idebenone-Loaded Solid Lipid Nanoparticles at 1.0 ml/min. Standard calibration curves for IDE determination were prepared at 280 nm wavelength and calibration curve linearity (r 2 > 0 999) was maintained over the range of concentrations tested (10 g/mL-0.1 g/mL). The retention time of IDE was 6 min.
HPLC Analysis
HPLC analyses of DZ were carried out using the same experimental conditions apart from column effluent monitoring that was performed at 242 nm. The retention time of DZ was 4 min and calibration curve linearity (r 2 > 0 999) was maintained over the range of concentrations tested (7.7 g/mL-0.77 g/mL).
Cell Cultures
Madin-Darby canine kidney (MDCKII-MDR1) cells (passages [16] [17] [18] [19] [20] were kindly donated by the Netherlands Cancer Institute and grown in Dulbecco's modified Eagle's medium (DMEM) containing glucose (4.5 g/l) (Euroclone, Italy) supplemented with 10% fetal bovine serum (Euroclone, Italy) penicillin (100 U/ml), streptomycin (100 g/ml) and 2 mM L-glutamine. The cells were kept at 37 C in an atmosphere of 95% air and 5% CO 2 .
Transport of IDE and IDE Loaded SLN Across MDCKII-MDR1 Cell Line
MDCKII-MDR1 cells were grown to confluence for 8 days. Cells were seeded at density of 6 × 10 4 cells/cm 2 on uncoated polycarbonate Transwell ™ filter inserts (3402 Corning Costar Corp., Germany, 3 m pore size, area: 1.12 cm 2 and the medium was changed every day. On the day of the experiment, cells were rinsed twice and equilibrated at 37 C for 30 min with the assay medium. The assay medium had the following composition: K 2 HPO 4 0.4 mM, NaHCO 3 25.0 mM, KCl 3.0 mM, MgSO 4 1.2 mM, CaCl 2 1.4 mM, NaCl 122.0 mM and glucose 10.0 mM. The pH was adjusted to 7.4 and the osmolarity was 300 mOsm/Kg. IDE-loaded SLN were freshly prepared and diluted in the assay medium containing the paracellular marker FITC-dextran 4000 (50 M) and the transcellular marker diazepam (75 M) 16 , so as to obtain two different IDE concentrations: 300 M (SLN A L1 -C L1 and 150 M (SLN A L2 -C L2 . Free IDE (300 M), dissolved in the assay medium containing 1% ethanol to ensure IDE solubility, was used as control. After the equilibration time, assay medium was aspirated and the cells were apically incubated with 0.5 ml of assay medium containing free IDE or IDE-loaded SLN for 3 h at 37 C. In the control wells, the same media without IDE-loaded SLN or free IDE were used. At t = 0, samples from the apical media were collected to precisely calculate the total amounts of IDE, DZ and FD4 present in the apical chamber. At fixed times intervals, withdrawals of 0.3 ml from the basolateral compartment were analyzed for IDE, DZ and FD4 content. The permeated FD4 was assayed by fluorimetric assay (Victor ™ X3, 2030 Multilabel Reader, Perkin Elmer, Italy, Excitation: 485 nm; Emission 535 nm).
Data Analysis
IDE and DZ fluxes ( g/cm 2 /h) through MDCK cells were calculated by plotting the cumulative amount of compound permeated against time and dividing the slope of the steady-state portion of the graphs by the area through which diffusion took place.
The apparent permeability coefficient P app was calculated using the following equation (Eq. (1)):
where S is the slope of the steady-state portion of the graphs ( g/h), A is the diffusion area of the monolayer, and C 0 is the initial drug concentration ( g/cm 3 . Results are expressed as mean values ± standard deviation (SD).
Data from different experimental groups were compared by a one-way ANOVA with p < 0 05 at 99% level of confidence (GraphPad Prism v. 4.00 GraphPad Software, Inc. San Diego, CA). Bonferroni post tests were used for posthoc contrast.
RESULTS AND DISCUSSION
SLN Characterization and Stability
Unloaded and IDE loaded SLN physico-chemical properties were similar to those previously reported. 16 As shown in Figure 2 , transmission electron microscopy (TEM) analyses of the SLN under investigation showed spherical particles with no evident sign of aggregation. Since similar images were obtained from all the SLN under investigation we reported only one picture as example. 
As reported in the literature, [11] [12] DSC analysis can be used to determine the physical state of the core lipid in SLN. The nanocrystalline size of the lipids in the SLN is thought to be responsible for the lowering of the melting peak temperature of the lipid core compared to that of bulk lipid. 31 DSC studies were performed both on unloaded and IDE-loaded SLN. The calorimetric behaviour of cetyl palmitate (CP) and one of the SLN investigated (unloaded SLN B) is depicted in Figure 3 . The calorimetric curve of CP bulk showed a broad peak at about 39 C and a main peak at about 50.5 C while unloaded SLN B exhibited a well defined peak at about 42 C and a shoulder at 38 C. Similar behaviours were observed for all other unloaded and IDE-loaded SLN (data not shown). The melting peak of loaded or unloaded SLN was observed at a temperature about 12-14 C lower than the bulk CP, suggesting that CP located in the core of the SLN was in the solid state. As reported by others, 32 these results confirmed that solid lipid nanoparticles were prepared. All the tested SLN showed physiological pH (7.25-7.39) and osmolarity (291-323 mOsm/Kg) values, a mean particle diameter in the range of 33-63 nm, a single peak in size distribution, and a potential ranging from +3.14 to −2.89 mV (Table II) . When incorporating IDE into SLN A or B, a decrease of particle size was observed while IDE addition to SLN C did not significantly affect particle size. A lower polidispersity index (P.I.) after loading the active ingredient was observed only for SLN B. Previous studies on SLN loaded with coenzyme Q 10 , a compound structurally related to IDE, 33 reported that this active agent was in part homogenously dispersed within the SLN matrix and in part arranged in separate nanoaggregates. A different status of IDE into the solid lipid matrix could lead to different interactions with the surfactant layer depending on the type of surfactant used to prepare these SLN, that, Table II , a correlation, although not linear, between surfactant lipophilicity and droplet size of unloaded SLN was observed, since the higher the surfactant lipophilicity, the smaller the particle size. Furthermore, since isoceteth-20 has a branched acyl chain while oleth-20 and ceteth-20 have linear acyl chains, unsaturated and saturated respectively, a different packing of the surfactant and co-surfactant molecules at the interface could be expected. Being IDE a lipophilic active agent (Log P 3.49, calculated using Advanced Chemistry Development Software Solaris V. 4.67) its loading into these SLN could affect particle curvature radius at different extent depending on its ability to penetrate the tail group region of the surfactant layer, likely owing to hydrophobic interactions occurring between the lipophilic active agent and the surfactant at the interfacial layer. Therefore, a lower IDE interaction with the least lipophilic surfactants (ceteth-20 and isoceth-20) could be expected with no change of particle size. However, the results of our studies showed a decrease of particle size upon addition of IDE to SLN A and B, thus suggesting that in our experiments the structure of the surfactant may play a more important role in determining surfactant/active agent interactions. Further studies are ongoing to better understanding the interactions taking place between IDE and the different surfactants and its state of dispersion within the lipid matrix. As reported in the literature, 34 there is a correlation between the HLB temperature (or PIT temperature) and the surfactant HLB: as the surfactant HLB increases the HLB temperature increases as well and the higher the HLB temperature, the greater the formulation stability. Therefore, formulations containing surfactants showing similar HLB could be expected to have similar PIT values and similar stability. As shown in Table II room temperature for two months, particle size of IDEloaded SLN A increased while no significant change was observed after particle sizing of all the other formulations (Fig. 4) . These findings could be due to the occurrence of aggregation phenomena between nanoparticles, leading to the growing of mean size. As can be observed in Table II , differences in zeta-potential values were too small to explain the particle increase of SLN A L . On the contrary, the lower stability of IDE-loaded SLN A could be attributed to the structure of the surfactant used to prepare these SLN. A lower intercalation of IDE between the tail group region of the surfactant layer could occur, when the surfactant had a branched acyl chain (isoceteth-20), with a resulting looser packing of the surfactant layer that would increase aggregation phenomena. Stability tests, performed at room temperature and 37 C, did not show any significant variation of pH and osmolarity values (data not shown). However, during storage at 37 C, less stability in terms of particle size for all the formulations tested was observed (data not shown). As reported in the literature, 12 less stability at higher temperature could be due to an increase of energy into the system leading to particle aggregation and size growth. Our results suggest that the different structure of the acyl chain of the primary surfactants could strongly affect IDEloaded SLN particle size and stability properties during storage likely by different interactions between the active agent and the tail group region of the surfactant layer and/or different packing of the surfactant and co-surfactant molecules at the interface.
Unloaded and IDE-loaded SLN stability was also investigated in SBF, a medium simulating plasma saline composition and osmolarity value. 29 30 As shown in Figure 5 , no significant change of particle size during 24 h was observed for IDE-loaded SLN at the different dilutions (IDE 300 M and IDE 150 M) used for in vitro transport experiments. Similar results for unloaded SLN (SLN A-C) were obtained (data not shown). These data indicate that no change of SLN particle size could be expected to occur during in vitro transport study. 
Transport Studies
To date, overcoming the BBB still represents a challenge for the administration of drugs to the CNS. In this work, we investigated the effects of SLN composition on IDE permeability across MDCKII-MDR1 cell monolayers, taken as in vitro method to estimate drug permeation across the BBB. 20 35 About the cells, transport studies across MDCKII-MDR1 were performed within an average time of 3 h, which appeared a suitable frame time for sake of cell vitality. 20 36 According to the literature, 23 all monolayers tested showed transepithelial electric resistance (TEER) values higher than 122 cm 2 to ensure the reliability of our in vitro permeability results.
About SLN releasing the antioxidant IDE, the diffusion of the drug through MDCKII-MDR1 was supposed to be passive due to the lack of any targeting moiety in these SLN and to their small particle size. As shown in Table III , an increase of IDE concentration in the vehicle provided an increase of IDE flux, thus indicating that Fick's I law could be applied to calculate IDE permeability parameters. Previous in vitro release studies 16 showed that the amount of IDE released from these SLN during 3 h was much higher than that permeated across MDCKII-MDR1, thus indicating that the rate-liming step was IDE permeation rather than its release from the vehicle. IDE permeability from SLN A-C was 0. free IDE. As evidenced by the calculated relative P app , no significant difference was observed comparing IDE permeation from all the SLN tested. Although IDE permeation from SLN was lower than that observed using free IDE, it is of worth to note that by encapsulating IDE in SLN A-C, the use of a solvent like ethanol could be avoided. In fact, an organic solvent is required for IDE dissolution, due to IDE poor water solubility (3 g/mL). 16 However, a solvent like ethanol could not be tolerated for IDE parenteral administration, due to its well-known toxic effects. 37 Therefore, IDE-loaded SLN could make feasible the parenteral administration of this drug in an aqueous vehicle. Furthermore, the amount of IDE permeated from SLN A-C after 3 h was similar to the amount that in previous in vitro biological experiments on astrocyte cell cultures showed an antioxidant activity higher than free IDE. 16 To better clarify the diffusion mechanism of IDE from SLN, the P app values of the transcellular marker DZ (Table IV) and the paracellular marker FD4 (Table V) were determined. All tested SLN at both IDE concentrations exhibited lower P app values of DZ than control (Table IV) and, at the same time, P app values of FD4 did not change in comparison to control marker value (Table V) . The reduction of DZ transit could be related to a transcellular diffusion mechanism and a competition mechanism arising between these lipophilic molecules (IDE log P 3.5; DZ log P 3.0) could occur when each of them tries to permeate directly the lipid bilayer of the cells. Previous studies 36 pointed out that a lipophilic Ara-C conjugate was able to overcome MDCKII-MDR1 barrier by the transcellular pathway, as confirmed by the reduction of P app value of DZ. In the case of free IDE, the transit of DZ was comparable to that observed in the case of SLN (Table IV) . On the other hand, free IDE reduced markedly the transit of FD4 through the paracellular pathway (Table V) In both cases, free IDE was dissolved in the assay medium containing 1% ethanol to ensure its solubility in the medium. Since ethanol could affect DZ and/or FD4 permeation through MDCKII-MDR1 cells, we tested the effect of the mixture phosphate buffer solution (PBS)/EtOH (99/1 v/v), in which IDE was dissolved, on DZ and FD4 permeation. As reported in Tables IV and V, EtOH reduced both the transit of DZ and FD4 compared to the investigated SLN. These results could indicate that the presence of ethanol in the assay medium could reduce DZ partitioning from the vehicle into the membrane bilayer causing a reduction of P app of DZ. This hypothesis could be supported by the higher solubility of DZ in ethanol than in water (26.20 g/L and 2.86 g/L, respectively).
On the other hand, the significant reduction (p < 0 001) of P app of FD4 in the presence of ethanol could suggest a slight toxic effect of ethanol towards the tight junctions that could induce the cells to defend themselves from the organic solvent by "re-enforcing" the same tight junctions. Nevertheless, the presence of ethanol in the assay medium did not affect cell culture viability as TEER values were always maintained higher than 122 cm 2 . As shown in Table V , none of the tested IDE-loaded SLN showed an enhancement effect on FD4 permeability, thus revealing that SLN administration did not significantly alter the tight junctions of MDCKII-MDR1 cells Montenegro et al. In Vitro Evaluation on a Model of Blood Brain Barrier of Idebenone-Loaded Solid Lipid Nanoparticles and supporting the hypothesis that permeation occurred through the transcellular pathway.
CONCLUSIONS
IDE permeation from IDE-loaded SLN across MDCKII-MDR1 cell monolayers, selected as an in vitro model of BBB, was lower than that of free IDE and no effect of different SLN compositions was observed. However, the amount of IDE that permeated from these SLN was similar to the amount that in previous in vitro biological experiments on astrocyte cell cultures showed an antioxidant activity higher than free IDE. Since IDE is a poor water soluble drug, its dissolution as free drug in an aqueous medium at therapeutic concentrations requires the use of an organic co-solvent like ethanol. IDE loading into SLN may represent an advantageous strategy to obtain aqueous vehicles containing IDE without the help of an organic solvent.
Results of in vitro transport studies, performed using FD4 and DZ as markers of the paracellular pathway and the transcellular pathway, respectively, show that IDE could permeate via a transcellular pathway. Further in vitro and in vivo studies are planned to better understand the fate of SLN after their administration and the mechanisms by which IDE permeation occurs.
In conclusion, these carriers may represent a promising strategy for IDE delivery to the brain, which deserves further investigations from a pharmacokinetic viewpoint.
